Category Archives: Pharmacogenomics

Trivedi MH. Major Depressive Disorder in Primary Care: Strategies for Identification.J Clin Psychiatry. 2020;81(2).

Roca M, Vives M, Lpez-Navarro E, Garca-Campayo J, Gili M. Cognitive impairments and depression: a critical review. Actas Esp Psiquiatr. 2015;43(5):18793.

PubMed Google Scholar

Roca M, Monzn S, Vives M, Lpez-Navarro E, Garcia-Toro M, Vicens C, et al. Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study. J Affect Disord. 2015;171:8592.

Article PubMed Google Scholar

Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):202940.

Article CAS PubMed Google Scholar

Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, et al. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43(3):53951.

Article CAS PubMed Google Scholar

Pridmore S, Auchincloss S. Preventing suicide: a global imperative. Australasian Psychiatry. 2015;23(1):812.

Article Google Scholar

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):135766.

Article CAS Google Scholar

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):190517.

Article PubMed Google Scholar

Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord. 2014;152154:4551.

Article PubMed Google Scholar

Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 19962013. Psychiatr Serv. 2014;65(8):97787.

Article PubMed Google Scholar

Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 2014;60(1):539.

Article CAS PubMed Google Scholar

Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2018;241:48491.

Article PubMed Google Scholar

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:5967.

Article PubMed Google Scholar

Tiwari AK, Zai CC, Altar CA, Tanner JA, Davies PE, Traxler P, et al. Clinical utility of combinatorial pharmacogenomic testing in depression: a canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry. 2022;12(1):101.

Article CAS PubMed PubMed Central Google Scholar

Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):15161.

Article CAS PubMed PubMed Central Google Scholar

Perlis RH, Dowd D, Fava M, Lencz T, Krause DS. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety. 2020;37(9):83441.

Article PubMed Google Scholar

Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder?: a systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(6):7209.

Article PubMed Google Scholar

Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21(8):55969.

Article CAS PubMed Google Scholar

McCarthy MJ, Chen Y, Demodena A, Leckband SG, Fischer E, Golshan S, et al. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol (Oxford England). 2021;35(8):9921002.

Article Google Scholar

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

Article PubMed PubMed Central Google Scholar

Higgins JP, Altman DG, Gtzsche PC, Jni P, Moher D, Oxman AD, et al. The Cochrane collaborations tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article PubMed PubMed Central Google Scholar

Richardson MGP, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7:1928.

Article Google Scholar

Shan X, Zhao W, Qiu Y, Wu H, Chen J, Fang Y, et al. Preliminary clinical investigation of Combinatorial Pharmacogenomic Testing for the Optimized treatment of Depression: a randomized single-blind study. Front Neurosci. 2019;13:960.

Article PubMed PubMed Central Google Scholar

Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:1007.

Article PubMed Google Scholar

Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin Psychopharmacol Neurosci. 2018;16(4):46980.

Article CAS PubMed PubMed Central Google Scholar

Winner JG, Carhart JM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16(89):21927.

PubMed Google Scholar

Prez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Sez-Navarro C, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17(1):250.

Article PubMed PubMed Central Google Scholar

Singh AB. Improved antidepressant remission in Major Depression via a pharmacokinetic pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci. 2015;13(2):1506.

Article PubMed PubMed Central Google Scholar

Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):3747.

Article CAS PubMed Google Scholar

Stingl J, Viviani R, Polymorphism. CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2015;277(2):16777.

Article CAS PubMed Google Scholar

Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018;175(9):87386.

Article PubMed PubMed Central Google Scholar

Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3(6):58590.

Article PubMed Google Scholar

Hicks JK, Bishop JR, Sangkuhl K, Mller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):12734.

Article CAS PubMed PubMed Central Google Scholar

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Mller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):3744.

Article CAS PubMed Google Scholar

Juki MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 genotype on Escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018;175(5):46370.

Article PubMed Google Scholar

Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):12635.

Article PubMed Google Scholar

Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473500.

Article CAS PubMed Google Scholar

Szegedi A, Rujescu D, Tadic A, Mller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5(1):4953.

Article CAS PubMed Google Scholar

Arias B, Serretti A, Lorenzi C, Gast C, Cataln R, Faans L. Analysis of COMT gene (val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of european origin. J Affect Disord. 2006;90(23):2516.

Article CAS PubMed Google Scholar

Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed japanese patients. Neuropsychobiology. 2006;53(4):18695.

Article CAS PubMed Google Scholar

Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):91358.

Article CAS PubMed Google Scholar

Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29(3):192209.

Article CAS PubMed Google Scholar

Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761804.

Article CAS PubMed Google Scholar

Bradford LD. CYP2D6 allele frequency in european Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):22943.

Article CAS PubMed Google Scholar

Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2(6):45762.

Article CAS PubMed Google Scholar

Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2021;54(1):517.

Article PubMed Google Scholar

Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.Frontiers in Pharmacology. 2020;11.

Benitez J, Cool CL, Scotti DJ. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med. 2018;15(6):48194.

Article CAS PubMed Google Scholar

Perlis RH, Mehta R, Edwards AM, Tiwari A, Imbens GW. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: a propensity-score matched study. Depress Anxiety. 2018;35(10):94652.

Article CAS PubMed Google Scholar

Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for Mental Health Care in a primary care setting. Clin Ther. 2017;39(3):592602e1.

Article PubMed Google Scholar

Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds CF, Berk M, et al. Antidepressant prescribing in the precision medicine era: a prescribers primer on pharmacogenetic tools. BMC Psychiatry. 2017;17(1):60.

Article PubMed PubMed Central Google Scholar

Link:
Effect of pharmacogenomics testing guiding on clinical outcomes in ... - BMC Psychiatry

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalDatas report on Immuno-oncology in Pharmaceuticals: Microbiota restoration therapy.

According to GlobalDatas Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Microbiota restoration therapy is a key innovation area in immuno-oncology

Microbiota restoration therapy can be composed of human faecal material containing viable gut flora from a patient or donor, and include a diluent and a cryoprotectant. The human faecal material is screened before using it in the restoration therapy for any pathogenic microorganisms.

GlobalDatas analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 240+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of microbiota restoration therapy.

Key players in microbiota restoration therapy a disruptive innovation in the pharmaceutical industry

Application diversity measures the number of different applications identified for each relevant patent and broadly splits companies into either niche or diversified innovators.

Geographic reach refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from global to local.

Source: GlobalData Patent Analytics

Probiotical is the leading patent filer for microbiota restoration therapy. Probiotical is a manufacturer of probiotics and synbiotics products. The companys activities consist of several stages of research and development, strain isolation, characterisation and production of probiotic strains for the prevention and treatment of various diseases, and design and implementation of specific probiotics and synbiotics finished products in many therapeutic areas, supported by clinical studies.

In terms of application diversity, Fate Therapeutics is the top company, followed by Imstem Biotechnology and the Spanish National Research Council. By means of geographic reach, the Spanish National Research Council holds the top position. While GI Innovation and Vitacare stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalDatas latest thematic research report on Pharmaceutical.

Get industry leading news, data and analysis delivered to your inbox

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalDatas Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the worlds largest industries.

See the original post:
Who are the leading innovators in microbiota restoration therapy for ... - Pharmaceutical Technology

by Anand.K

The Human Genome Project is undoubtedly one of the most important and remarkable scientific feats in history and more recently, On March 31, 2022, the Telomere-to-Telomere (T2T) consortium announced that it had filled in the remaining gaps (roughly 8%) and produced the first truly complete human genome sequence. Highly accurate and long-read sequencing had finally removed technology limitations, enabling comprehensive studies of genomic variation across the entire human genome, which we expect to drive future discovery in human genomic health and disease.

continued below

Genomics applications in Rare Disorder Diagnosis Recently, a 19 month old child in the UK received lifesaving gene therapy for a rare disorder called metachromatic leukodystrophy. The ability to understand genomes quickly and inexpensively has led to advances in the diagnosis of rare disorders, thus helping families end their diagnostic odysseys. While rapid advances have been made in rare disorders, there are many disorders that may yet be discovered. Large scale research studies that are population specific would be required to understand the pattern of such diseases. This can provide significant relief to families with members suffering from such disorders, as well as help them understand the risk to future generations. 250+ such disorders have been identified. Through extensive genetic testing, it is possible to accelerate diagnosis and treatment options for patients living with rare diseases. Collaborations between public health organizations and private institutions, along with advocacy for mandatory new-born screening, can aid in reducing the inequalities that exist.

Prenatal testing to identify genetic disorders early in pregnancy Prenatal genetic tests required a pregnant woman to undergo invasive procedures to obtain a fetal DNA sample. Tests like amniocentesis and chorionic villus sampling comes with associated risks to pregnancy. With DNA sequencing, it is now possible to test the pregnant lady's blood for genomic variants in an unborn baby. NIPT (Non Invasive Prenatal Testing) or cell-free fetal DNA testing is now being extensively used to detect Down syndrome. With rapid advances in genomics, it is likely that we may be able to detect other genetic conditions very early.

In 2012, a new technique called CRISPR was invented that borrowed tools from bacteria to effectively edit any DNA in any organism. CRISPR is making it possible to edit genomes cheaper, faster, and more accurately than all previous methods. While CRISPR is now being used to study diseases, advances in this technology can also help in treating diseases. Research is being underway for Sickle Cell Disease and HIV. CRISPR has the potential to change gene therapy, and while it is still in its early stages, this could pave the way for new treatment options for a variety of life-threatening diseases.

The global genomics market size is projected to reach USD 94.65 billion by 2028, exhibiting a CAGR of 19.4% during the forecast period. While India is a land of 1.3 billion genomes and makes up 20% of the worlds population, the DNA sequences of our people only make up about 0.2% of global genetic databases. Therefore, we have a long way to go before we are able to reap the benefits of the genomics revolution at scale.

In the Union Budget 2022, Finance Minister Ms. Nirmala Sitharaman identified genomics as one of the sunrise opportunities and stated that the government will implement supportive policies to boost domestic capacities. Industry-academia collaborations, funding for research, and supportive regulatory and policy frameworks can truly transform how genomics can help healthcare delivery in India.

Anand.K, Chief Executive Officer, SRL Diagnostics

(DISCLAIMER: The views expressed are solely of the author and ETHealthworld does not necessarily subscribe to it. ETHealthworld.com shall not be responsible for any damage caused to any person / organisation directly or indirectly.)

Join the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis.

Here is the original post:
The Future of Genomics in India - ETHealthWorld

Genomics and Precision Medicine Expo taking place on May 23 and 24 2023 at ExCeL London has announced its top 5 highlights for this years inaugural conference.

The event, which is being run in partnership with Genomics England, will explore the latest advancements and developments in genome sequencing and genomic testing, and the immediate and future potential for the development of precision medicine within the NHS and beyond.

Content throughout the two days will cover topics including discovery, research, development, and regulatory assessment, through to delivery, supply and patient referral.

Lucy Clarke, event manager of Genomics and Precision Medicine Expo, said: The event is a unique chance to discover critical updates, gain practical learnings that you can apply to your own work, and share insights with like-minded peers across patient care and science. With the UK being a key world leader in genomics testing and life sciences, there is a wealth of knowledge to be shared at the Genomics and Precision Medicine Expo.

The first day includes a session on precision cancer medicine: progress, limitations and opportunities. Precision medicine is the desire to tailor each persons treatment according to the underlying biology of their disease.

Also on the first day, a talk in the afternoon will examine implementing whole genome sequencing into routine clinical practice. All children in the U.K. with cancer are eligible for somatic and germline whole genome sequencing (WGS) via the NHS Genomic Medicine Service. Jack Bartram, a consultant pediatric hematologist at Great Ormond Street Hospital for Children (GOSH), will describe experiences of using WGS for hematological malignancies to obtain, analyze and clinically integrate results in a meaningful timeframe.

Another highlight is a panel discussion on navigating patient consent in cancer genomics. The use of genomic testing in routine care brings benefits for patient care and treatment, but it can also present new challenges for clinicians around consent. In this panel session involving representatives from Genomics England and The Royal Marsden NHS Foundation Trust, guests will explore different scenarios and approaches to consenting cancer patients for genomic testing.

On the second day, an afternoon presentation will look at the role of nurses in transforming genomic healthcare. The application of genomics in everyday practice is now a reality in cancer care and in rare diseases. Tootie Bueser, director for nursing & midwifery and chief nurse Southeast Genomic Medicine Service Alliance and North Thames Genomic Medicine Service Alliance will explore how nurses have an important role in transforming care through genomics and need access to education, training and other resources to maximize this opportunity.

The final highlight is a session on pharmacogenomics, hosted by Nisha Shaunak, associate chief pharmacist Cancer, TRU and Surgery Clinical Group, Guys & St Thomas NHS Foundation Trust.

Co-located with the Oncology Professional Care, Genomics and Precision Medicine Expo, the event is free to attend for registered healthcare professionals and individuals working in the field of genomics and precision medicine (excluding commercial companies) and is fully CPD accredited.

The co-located events feature 150+ sessions across seven focused theaters with product and service providers showcasing the latest innovations on the exhibition floor.

Genomics and Precision Medicine Expo intends to capture the interest of Public Health and ICS leaders, CCIOs within the NHS and private sector, clinicians working in acute and primary care who wish to develop their knowledge and understanding of the fast-moving developments in this sector, and clinical and biomedical scientists.Attendance is free for UK healthcare professionals and individuals working in the fields of genomics and precision medicine (in non-commercial roles). Register here: genomicsprecisionmedicine.co.uk

See original here:
5 highlights at first Genomics and Precision Medicine Expo - Labiotech.eu

In the 1970s, NIH research gave us genetic engineering and launched what is today the $100 billion biotechnology industry, a major source of high-paying U.S. jobs. Virtually every biomedical research lab and pharmaceutical company uses the power of the genomic revolution every day to demystify diseases and search for new cures. Companies today can read the entire DNA sequence of an individual for less than $1,000, and the cost is dropping quickly. This ability to study massive amounts of DNA has helped the field of pharmacogenomics mature rapidly. In this area of science, researchers match DNA patterns in individuals with how they respond to medications. The goal is to move away from one-size-fits-all dosing because we now know that many factors aside from sex, age, and body size influence how our bodies react, ordont, to many drugs. Research results in this important area of biomedicine have prompted FDA to include pharmacogenomic information in drug labeling, toward more precise and safer drug responses for patients. A significant goal of precision medicine is to implement this strategy broadly in medical care focusing on the right drug at the right dose at the right time for the right patient.

Previous: Cancer Immunotherapy Next: Rare Diseases

This page last reviewed on February 28, 2023

See the original post:
Pharmacogenomics | National Institutes of Health (NIH)

Molecular Diagnostics Market is estimated to be US$ 45.30 billion by 2030 with a CAGR of 11.5% - By PMI  EIN News

View post:
Molecular Diagnostics Market is estimated to be US$ 45.30 billion by 2030 with a CAGR of 11.5% - By PMI - EIN News